Eisbach Bio doses first patient in Phase 1/2 Trial for first-in-class drug to take on Refractory Advanced Solid Tumors

The trial is being conducted at The University of Texas MD Anderson Cancer Center. It is co-funded by the Cancer Focus Fund.